Type Private Key people Marjanne Prins (CEO) Number of employees 4 | Founder Marjanne Prins Founded 2007 | |
Industry pharmaceutical industry Headquarters Arnhem, The Netherlands | ||
OrgaNext is a Dutch pharmaceutical company established in 2007 with no marketed products as of 2015. The company was founded by Marjanne Prins, who also serves as the chief executive officer. As of the end of 2014, the company had four employees, all former employees of Organon International who left the company when it was acquired by Schering-Plough in 2007. The focus of the company is the development of a treatment for age-related muscle atrophy, specifically a "low-dose, short-term Recovery Booster therapy, a combination of nandrolone decanoate and Vitamin D3 (NDD)" for administration to victims of hip fractures. In 2011, the company received a WIPO patent for a general treatment for "frailty" of which NDD was a specific instance.
OrgaNext was established with seed financing of US$3,200,000 and was seeking, as of late 2014, an infusion of US$31,000,000 through Series A and Series B venture capital funds.